Canaccord lowered the firm’s price target on Zevra Therapeutics (ZVRA) to $23 from $25 and keeps a Buy rating on the shares. The firm ...

McFarlane, Zevra's President and Chief Executive Officer. "After years of tireless effort, our team has achieved a major milestone with FDA approval of MIPLYFFA™ (arimoclomol), and we're celebrating ...

Analyst Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on Zevra Therapeutics (ZVRA – Research Report) and increased the ...

Zevra Therapeutics The U.S. Food and Drug Administration (FDA) approved Zevra’s MIPLYFFA™ (arimoclomol) capsules as an orally delivered treatment for Niemann-Pick disease type C (NPC). MIPLYFFA™ is ...

In the third quarter, we reported net revenue of $3.7 million, which includes $2.6 million in net reimbursements from the French EAP for arimoclomol and $1.1 million of royalties and other ...

Zevra Therapeutics (NASDAQ:ZVRA) is scheduled to announce Q3 earnings results on Tuesday, November 12th, after market close.

Emrosi is expected to be available in the first quarter or early second quarter of 2025. The Food and Drug Administration has approved Emrosi ™ (minocycline hydrochloride extended-release ...

In cross-sectional analysis, children with asthma had lower scores on episodic memory, processing speed, inhibition, and attention. HealthDay News — Asthma is associated with memory difficulties ...